Research Brief
Storing AOD-9604: Best Practices
21 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: julio de 2026
Péptido Liofilizado (Sin Abrir)
El polvo liofilizado de AOD-9604 es estable a temperatura ambiente hasta 90 días. Para almacenamiento a largo plazo, mantener a -20°C (-4°F) en un contenedor sellado y desecado. Evitar la exposición directa a la luz.
Péptido Reconstituido
Reconstituir con Agua Bacteriostática (0.9% alcohol bencílico) o Agua Estéril para inyección. Una vez reconstituido, almacenar a 2°C a 8°C (36°F–46°F) y usar dentro de 14–21 días. No congelar la solución reconstituida.
Precauciones de Manejo
- Permitir que el vial alcance la temperatura ambiente antes de abrirlo para prevenir la condensación.
- No agitar vigorosamente; girar suavemente durante la reconstitución.
- Usar técnica aséptica para todas las preparaciones.
- Desechar cualquier solución que aparezca turbia o contenga material particulado.
Referencias
- Heffernan, M., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic research application in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182-5189.
- Ng, F. M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274-278.
- Ng, F. M. & Bornstein, J. (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol, 235(1), E55-E59.
- Ng, F. M., et al. (2000). Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol, 25(3), 287-298.
- Kwon, D. R. & Park, G. Y. (2015). Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci, 45(4), 426-432.
- Kwon, D. R., et al. (2020). Regenerative effects of intra-articular injection of AOD 9604 combined with hyaluronic acid in a rabbit model of collagenase-induced osteoarthritis. compound Des Devel Ther, 14, 2193-2201.
- Lateral Pharma Pty Ltd. (2020). LAT8881 (AOD9604) host-protective experimental protocol for influenza A virus infection. Clinical development update.
- Wu, Z., et al. (1993). The structural determinants of the lipolytic fragment (residues 177-191) of human growth hormone. Int J Pept Protein Res, 41(5), 432-438.
- Ng, F. M., et al. (1990). Action of a synthetic lipotropic peptide of human growth hormone on lipogenesis in rats. J Mol Endocrinol, 5(3), 265-271.
- Heffernan, M., et al. (2000). The effects of AOD9604 on beta-3 adrenergic receptor expression and lipolysis in obese mice. Obesity Research, 8(S1), abstract.
- Groenewegen, W. A., et al. (2004). Oral AOD9604 reduces body fat in Zucker rats by selective fat mass reduction without effect on lean body mass. Appetite, 42(3), abstract.
- Ng, F. M. & Roupas, P. (1999). Anti-lipogenic action of the C-terminal fragment 177-191 of human growth hormone. Res Commun Mol Pathol Pharmacol, 106(1-2), 35-48.
- Tomer, Y. & Bhargava, A. S. (1999). Growth hormone receptor and signal transduction. In: Molecular Biology of Growth Hormone Receptors. Springer.
- Wu, Z., et al. (1994). Mapping the functional domains of human growth hormone required for metabolic activity. J Biol Chem, 269(22), 15523-15530.
- Stier, H., et al. (2013). tolerability and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab, 3(1-2), 7-15.
- Metabolic Pharmaceuticals Limited. (2007). Metabolic’s obesity compound – Phase 2B clinical trial results. ASX Announcement, 27 June 2007.
- Thompson, G., et al. (2004). Phase 2b clinical trial results for AOD9604. Presented at the International Congress on Obesity.
- Kwon, D. R., et al. (2019). Regenerative effects of AOD9604 with or without hyaluronic acid on tendon healing in a rat Achilles tendon injury model. compound Des Devel Ther, 13, 4173-4186.
- Stier, H. & Kenley, D. (2012). Preclinical and clinical tolerability review of AOD9604. Regul Toxicol Pharmacol, 64(2), S34-S35.
- U.S. Food and Drug Administration. (2023). Bulk Drug Substances Used in Compounding Under Section 503B. FDA.gov.
- World Anti-Doping Agency. (2024). The Prohibited List: International Standard. Section S2.
Preguntas de Investigación Relacionadas
Go Deeper
Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de AOD-9604→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.